CVKD - CIK 0001937993
The table below shows Cadrenal Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$3.00M | -$4.65M | -$1.84M | -$1.41M | -$43.70K |
| Capital expenditure | - | $3.25K | - | - | - |
| Investing cash flow | - | -$3.25K | - | - | - |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - | - |
Cadrenal Therapeutics, Inc. reported operating cash flow of -$12.60M for fiscal year 2025. That is down 71.3% from -$7.36M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Financing cash flow | $1.30M | $1.97M | $298.00 | $5.41M | $506.04K |